Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Hematopoietic Stem Cell Transplantation

Introduction to Hematopoietic Stem Cell Transplantation

  • Autologous stem cell transplantation (ASCT) is effective for transplant-eligible patients with multiple myeloma, with improved progression-free survival, according to the Mayo Clinic Proceedings 1
  • ASCT is effective for relapsed/refractory lymphoma, particularly in chemosensitive relapse, and should be considered for consolidation in second or third remission, as recommended by the National Comprehensive Cancer Network 2

Indications for Hematopoietic Stem Cell Transplantation

  • Allogeneic HSCT is the only potentially curative treatment for myelodysplastic syndrome (MDS), and is recommended for higher-risk MDS patients under 70 years without major comorbidities, with long-term survival rates of 25-45% reported 3, 4
  • HLA-matched sibling donor (MSD) HSCT is effective for patients with sickle cell disease (SCD) at risk of neurologic injury or with recurrent vaso-occlusive crises, with best outcomes when performed at the earliest age possible 5
  • Stem cell transplantation (SCT) should be discussed in selected cases of Waldenström's macroglobulinemia, with ASCT being feasible and effective for high-risk patients eligible for transplant, most beneficial when offered at early relapses 6

Patient Selection and Evaluation

  • Patient selection should be based on disease risk stratification using the Revised International Prognostic Scoring System (IPSS-R), considering patient age, comorbidities, and donor availability 7, 4, 3
  • Higher-risk MDS patients should be referred for transplant evaluation at diagnosis, with consideration of proceeding to transplant as soon as a donor is identified 4, 3
  • Lower-risk MDS patients should follow surveillance with transplantation only upon disease progression 3

Pre-Transplant Therapy

  • Hypomethylating agents (azacitidine or decitabine) are recommended as a bridge to transplantation, especially for patients with ≥10% bone marrow blasts, with at least six cycles recommended 8, 4, 3
  • Cytoreductive therapy is recommended prior to transplant if bone marrow blasts ≥10%, with options including hypomethylating agents (HMAs) and intensive chemotherapy 7, 3
  • Intensive chemotherapy (ICT) can be considered for younger patients with highly proliferative disease without adverse cytogenetics or TP53 mutations, with complete remission rates around 50% 3

Donor Selection

  • The National Comprehensive Cancer Network recommends standard donors in the following order of preference: HLA-identical siblings, syngeneic donors, and 8/8 or 10/10 matched unrelated donors (MUDs) 7
  • Alternative donors should be considered for higher-risk patients when no matched donor is available within a reasonable timeframe 7, 3
  • Donor characteristics, including age, sex, and cytomegalovirus (CMV) status, should be considered during selection 7, 3

Pre-Transplant Management

  • Iron overload should be addressed before transplant, with iron chelation recommended for patients with significant transfusion burden 4
  • Collecting stem cells before exposure to certain agents, such as fludarabine, is recommended 6

Post-Transplant Management

  • Graft-versus-host disease (GVHD) requires careful management, although specific recommendations are not provided 7
  • Disease relapse remains a major challenge, with a probability ranging from 10-40%, particularly in higher-risk disease 7, 3
  • Pre-transplant therapy response, especially in patients with TP53 mutations, predicts poor outcomes 3

Prognostic Factors

Factor Association with Outcome
Performance status (Karnofsky status ≥80%) Better survival [7]
Comorbidity index Lower index correlates with better outcomes [7]
Bone marrow blast percentage <10% at time of transplantation improves outcomes [7]
Cytogenetics Very poor-risk and monosomal karyotypes have inferior outcomes [7]
Molecular mutations TP53, EZH2, and ETV6 are associated with poor prognosis [7]
  • The American Society of Hematology recommends considering these factors when evaluating patients for hematopoietic stem cell transplantation 4, 7